Dormant
KRO · Kronos Worldwide, Inc.
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on the last session; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Current thesis
Kronos Worldwide’s titanium-dioxide recovery needs higher third-quarter selling prices and continued segment profitability to validate August’s earnings rebound. The September 11 close of $8.14 has lost the earlier $8.20 shelf; a weekly close below $8.00 would invalidate the market thesis before that operating test.
Kill line
A weekly close below $8.00 invalidates the August recovery structure; third-quarter 2026 titanium-dioxide selling prices flat or lower sequentially, or a segment loss, would separately invalidate the operating thesis.
Pick status
Open commitment scored if the kill line above fires How this is scored →Latest analysis and events for KRO —
As of 20 September 2026, the latest FrontierPicks analysis for Kronos Worldwide, Inc. (KRO): Kronos Worldwide’s titanium-dioxide recovery needs higher third-quarter selling prices and continued segment profitability to validate August’s earnings rebound. The September 11 close of $8.14 has lost the earlier $8.20 shelf; a weekly close below $8.00 would invalidate the market thesis before that operating test.
Kill line: A weekly close below $8.00 invalidates the August recovery structure; third-quarter 2026 titanium-dioxide selling prices flat or lower sequentially, or a segment loss, would separately invalidate the operating thesis.
Current Thesis
Kronos Worldwide’s titanium-dioxide recovery needs higher third-quarter selling prices and continued segment profitability to validate the earnings rebound; a weekly close below $8.00 would invalidate the market thesis first. The recovery remains conditional: the company’s 2026-08-05 release attributed improved second-quarter earnings primarily to higher volumes and lower production costs, while selling prices remained below the year-earlier quarter. Q2 results
The change since the August coverage is weaker price confirmation. The adjusted market close was $8.14 on 2026-09-11, below the $8.20 mid-August shelf identified in the 2026-08-30 published note. The narrative is maturing — the August earnings release and Deutsche Bank’s 2026-08-25 target revision remain the dated supports, while the company’s release index reviewed on 2026-09-13 lists no subsequent announcement. This is an inference about the available evidence, not a measurement of investor flows. Company announcements
Bullish and bearish views on Kronos Worldwide, Inc.
The model's bull view on Kronos Worldwide, Inc. (KRO), in brief: The earnings rebound is measured. Kronos reported second-quarter 2026 net income of $15.2 million against a $9.2 million loss a year earlier; titanium-dioxide segment profit reached $41.0 million against $10.9 million. These figures establish a quarterly improvement, without… The bear view: Annual pricing remains below comparison. Both cases follow in full.
Bull Case
- The earnings rebound is measured. Kronos reported second-quarter 2026 net income of $15.2 million against a $9.2 million loss a year earlier; titanium-dioxide segment profit reached $41.0 million against $10.9 million. These figures establish a quarterly improvement, without establishing its durability. 2026-08-05 results
- Realized pricing has improved within 2026. The 2026-08-05 release reported that average titanium-dioxide selling prices increased 4% during the first six months of 2026. That supports the pricing-recovery hypothesis; flat or lower sequential prices in the third quarter would contradict its continuation. Company release
- An analyst revision supports valuation. Deutsche Bank raised its price target to $9 from $6 on 2026-08-25, according to the ratings coverage. This remains a third-party valuation opinion; a reversal of that revision would remove this supporting evidence. Analyst coverage
Bear Case
- Annual pricing remains below comparison. Second-quarter 2026 titanium-dioxide selling prices were 3% below the year-earlier period in the 2026-08-05 release. The quarterly earnings improvement therefore does not establish that pricing has fully recovered. Company release
- The valuation sample is narrow. StockAnalysis’s forecast page, last updated 2026-08-25, reports an $8.50 average target and a Hold consensus across two analysts. The sample is too small to support a claim of broad institutional agreement. Forecast data
- Price has lost intermediate support. The 2026-09-11 adjusted close of $8.14 lies below the previously identified $8.20 shelf. The inference is weaker confirmation of the recovery thesis; a weekly close back above $8.20 would contradict that specific structural concern.
Setup & Price Structure
The adjusted price series dated 2026-09-11 records an $8.14 close, an $8.86 trailing 52-week high and an 8.1% distance below that high. The shares were up 16.3% over three months, while the 14-period relative strength index was 49.8. These observations describe a positive three-month move with a retreat from the high; they do not identify who participated.
The $8.00 weekly-close boundary published on 2026-08-30 remains the thesis-break condition. The September 11 close is above that boundary but below the earlier $8.20 shelf, supporting a low-conviction continuation case ahead of the unresolved pricing test. A weekly recovery above $8.20 would improve the structure; it would not establish higher realized product prices.
The two-analyst sample dated 2026-08-25 is the available coverage-concentration evidence. Current short interest, retail-sentiment clustering and moving-average distance are missing from the evidence set, so no crowding conclusion is supported. Analyst sample
Catalyst Calendar (next 30 days)
- ~2026-11-04, estimated — Third-quarter results. ChartMill lists this earnings date, but the company’s announcement index reviewed on 2026-09-13 does not confirm it. This later event is included because reported sequential selling prices and segment profitability settle the operating thesis. Estimated calendar, Company announcements
Elapsed catalysts
- 2026-09-17 — Quarterly dividend payment. The board’s 2026-08-05 declaration specifies $0.05 per share, payable on this date. Payment implements the announced distribution; it supplies no new measurement of titanium-dioxide pricing. Dividend declaration (passed 3d ago)
What Would Change Our Mind
Loss of the remaining August price boundary would end the market recovery thesis: a weekly close below $8.00 is the observable condition retained from the 2026-08-30 publication. The 2026-09-11 close of $8.14 provides limited structural reassurance after the loss of the $8.20 shelf.
The operating case would be confirmed by third-quarter average titanium-dioxide selling prices rising sequentially while segment profit remains positive. Flat or lower sequential prices, or a segment loss, would invalidate that case. If the estimated 2026-11-04 date passes without results, the test remains unresolved; an unconfirmed calendar date alone is not evidence of operating failure.
Correlation Notes
This remains a single-company recovery case. Kronos’s 2026-08-05 release attributed sales gains to market-share gains across its markets, so its reported improvement cannot establish an industry-wide demand recovery. No measured return-correlation sample is available to support a group-momentum claim. Q2 results
Currency exposure also has opposing effects across the income statement. In the same release, Kronos estimated that exchange-rate changes increased second-quarter 2026 sales by approximately $10 million but reduced segment profit by approximately $12 million against the year-earlier quarter. Those disclosures do not support treating euro appreciation as an unqualified earnings benefit. Currency disclosures
Notes
- Kronos is a controlled company inside the Valhi (VHI) / NL Industries (NL) group; public float is a minority of shares outstanding and liquidity is correspondingly thin.
- Majority of production capacity sits in Europe, so reported results carry EUR/USD translation exposure and track European coatings and construction demand.
- Sell-side coverage is roughly two to four contributing analysts; aggregated targets move on very few revisions and aggregators disagreed materially in late August 2026.
- Quarterly dividend rate is $0.05 per share as of the 2026-08-05 declaration, unchanged from the rate declared in February 2026.
- Balance sheet carried $584.7M of total debt against $26.6M of cash at 2026-06-30, so working-capital swings drive the net-debt line quarter to quarter.
Related · shared themes
RXO
RXO, Inc.
Freight-cycle recovery intact; sell-side has fully caught up into a $20–35 battleground — bears $20 (Goldman 07-16, Susquehanna 07-14), bulls $30–35 (BMO $35 initiation 07-14, Stifel/Truist/Citi $30). Narrative matured from mispriced to consensus; the ~2026-08-05 Q2 print (adj EBITDA guide $27–37M vs $6M Q1) is the binary the whole re-rate discounts.
ARCB
ArcBest Corporation
ArcBest’s cost-reduction rebound failed its published price condition at the 2026-09-18 weekly close of $128.73. Third-quarter results still test recurring savings and preservation of the second-quarter 90.8% adjusted Asset-Based operating ratio, but cannot undo that invalidation.
JBHT
J.B. Hunt Transport Services, Inc.
J.B. Hunt’s freight-recovery thesis was invalidated by the 2026-09-18 weekly close below $265. The estimated 2026-10-15 report tests whether intermodal pricing and profit growth can support a separate recovery case after September’s cost warning.
XPO
XPO, Inc.
XPO, Inc.'s shipment-and-margin thesis failed its price test when the 2026-09-18 weekly close of $174.25 breached $185. The 2026-10-29 results still test shipment growth and management's guidance for an adjusted less-than-truckload operating ratio below 81%.